Tarcenib
Generic Name
Tarcenib 150 mg Tablet
Manufacturer
Medix Pharma
Country
Global
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| tarcenib 150 mg tablet | ৳ 600.00 | ৳ 6,000.00 |
Description
Overview of the medicine
Tarcenib 150 mg Tablet is an oral targeted therapy used in the treatment of certain types of non-small cell lung cancer (NSCLC) with specific Epidermal Growth Factor Receptor (EGFR) mutations. It works by blocking the activity of the EGFR protein, which helps slow down or stop the growth of cancer cells.
Uses & Indications
Dosage
Adults
The recommended dose is 150 mg orally once daily, with or without food, until disease progression or unacceptable toxicity.
Elderly
No specific dose adjustment is required for elderly patients (≥65 years) based on age.
Renal_impairment
No dose adjustment is required for mild to moderate renal impairment. For severe renal impairment or end-stage renal disease, data is limited, use with caution.
How to Take
Take the tablet orally once daily, at approximately the same time each day. It can be taken with or without food. Do not crush, chew, or split the tablet. If a dose is vomited, do not take an additional dose. Resume with the next scheduled dose.
Mechanism of Action
Tarcenib is an orally active, potent, and highly selective tyrosine kinase inhibitor (TKI) that irreversibly targets mutant forms of EGFR, including T790M, L858R, and exon 19 deletions. It blocks the intracellular phosphorylation of EGFR, preventing downstream signaling pathways involved in cell proliferation and survival.
Pharmacokinetics
Onset
Clinical effects may be observed within a few weeks of consistent therapy.
Excretion
Mainly excreted via feces (approximately 68%), with a smaller portion excreted via urine (approximately 14%).
Half life
Approximately 20-25 hours (elimination half-life).
Absorption
Rapidly absorbed after oral administration, peak plasma concentration reached within 4-6 hours. Absolute bioavailability is approximately 60-70%.
Metabolism
Primarily metabolized in the liver by cytochrome P450 enzymes, mainly CYP3A4, with minor contributions from CYP1A2 and CYP2D6. Active metabolites are formed.
Side Effects
Contraindications
- Hypersensitivity to tarcenib or any component of the formulation.
- Co-administration with St. John's Wort.
Drug Interactions
CYP3A4 Inducers (e.g., Rifampicin, Phenytoin)
May decrease tarcenib plasma concentrations, reducing efficacy.
CYP3A4 Inhibitors (e.g., Ketoconazole, Ritonavir)
May increase tarcenib plasma concentrations, requiring dose reduction.
Proton Pump Inhibitors (PPIs) and H2-receptor antagonists
May decrease tarcenib absorption due to pH elevation; administer antacids at least 2 hours before or 10 hours after tarcenib.
Storage
Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.
Overdose
There is no specific antidote for tarcenib overdose. Management of overdose should consist of general supportive measures. Monitor vital signs and observe for symptoms of toxicity. Seek emergency medical attention.
Pregnancy & Lactation
Pregnancy Category D. May cause fetal harm. Avoid use during pregnancy. Advise women of reproductive potential to use effective contraception during treatment and for at least 6 weeks after the last dose. It is not known if tarcenib is excreted in human milk; due to potential for serious adverse reactions in breastfed infants, advise lactating women not to breastfeed during treatment and for 6 weeks after the last dose.
Side Effects
Contraindications
- Hypersensitivity to tarcenib or any component of the formulation.
- Co-administration with St. John's Wort.
Drug Interactions
CYP3A4 Inducers (e.g., Rifampicin, Phenytoin)
May decrease tarcenib plasma concentrations, reducing efficacy.
CYP3A4 Inhibitors (e.g., Ketoconazole, Ritonavir)
May increase tarcenib plasma concentrations, requiring dose reduction.
Proton Pump Inhibitors (PPIs) and H2-receptor antagonists
May decrease tarcenib absorption due to pH elevation; administer antacids at least 2 hours before or 10 hours after tarcenib.
Storage
Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.
Overdose
There is no specific antidote for tarcenib overdose. Management of overdose should consist of general supportive measures. Monitor vital signs and observe for symptoms of toxicity. Seek emergency medical attention.
Pregnancy & Lactation
Pregnancy Category D. May cause fetal harm. Avoid use during pregnancy. Advise women of reproductive potential to use effective contraception during treatment and for at least 6 weeks after the last dose. It is not known if tarcenib is excreted in human milk; due to potential for serious adverse reactions in breastfed infants, advise lactating women not to breastfeed during treatment and for 6 weeks after the last dose.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
24 months from manufacturing date.
Availability
Globally, in specialized oncology centers and pharmacies
Approval Status
Approved by regulatory bodies (e.g., FDA, EMA, DGDA)
Patent Status
Patented
Clinical Trials
Tarcenib has been evaluated in several pivotal Phase III clinical trials (e.g., FLAURA, AURA3) demonstrating superior efficacy compared to standard chemotherapy or older EGFR TKIs in patients with specific EGFR mutations in NSCLC.
Lab Monitoring
- Liver function tests (ALT, AST, bilirubin) at baseline, every 4 weeks for the first 3 months, and then periodically as clinically indicated.
- Renal function tests (creatinine, BUN).
- Electrolytes (potassium, magnesium, calcium).
Doctor Notes
- Confirm EGFR mutation status prior to initiation of Tarcenib.
- Monitor for ILD symptoms; withhold Tarcenib if ILD is suspected and discontinue if confirmed.
- Regularly assess cardiac function, particularly in patients with pre-existing cardiac conditions.
Patient Guidelines
- Take Tarcenib exactly as prescribed by your doctor.
- Report any new or worsening symptoms, especially lung-related problems (e.g., shortness of breath, cough, fever), severe skin reactions, or eye irritation.
- Use effective contraception during treatment and for a specified period after the last dose.
Missed Dose Advice
If a dose is missed, take it as soon as you remember. However, if it is less than 12 hours before the next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed one.
Driving Precautions
Tarcenib may cause fatigue, dizziness, or vision disturbances in some patients. Patients should be cautious when driving or operating machinery if they experience these side effects.
Lifestyle Advice
- Avoid prolonged sun exposure and use sunscreen due to increased photosensitivity.
- Maintain good hydration and skin care to manage dermatologic side effects.
- Avoid grapefruit and grapefruit juice during treatment.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.
Other Medicines in Tarcenib Brand
Other medicines available under the same brand name
